Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
Despite Stormy Days Ahead, Pockets of Hope and Opportunity Remain
Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on pockets of emerging business opportunities, as well as a ... (6/1/2020)
   
Dealing with the Chinese Economy after COVID-19 (6/3/2020)
Chinese Antitrust Authority Imposes Maximum Fine In Rare Abuse Of Collective Dominance Case (6/1/2020)
Despite Stormy Days Ahead, Pockets of Hope and Opportunity Remain (6/1/2020)
Challenges Posed to Chinese Biotechs in Post-Pandemic Era (5/28/2020)
Considerations on the Protection of Remdesivir under Trademark Law (5/26/2020)
COVID-19 Makes Digital Care the Norm in China (5/21/2020)
As China Stumbles, India Plans Big Exports Push in Bulk Drugs (5/20/2020)
Trump Is Investing Millions to Bring Drug Making Back to US From India and China (5/20/2020)
How the Coronavirus Is Helping to Fix China’s Broken Healthcare System (5/19/2020)
China's Role in The Global Biotechnology Sector and Implications for US Policy (5/14/2020)
Strategic Considerations for Pharma MNCs in the Post-Coronavirus China (5/1/2020)
COVID-19 Is Reshaping the Pharmaceutical Supply Chain (4/27/2020)
SAMR Continues Focus on Pharma Sector Amid Covid-19 Outbreak, Fining API Distributors Over CNY 300M for Abuse of Dominance (4/23/2020)
New Report: Cascading Economic Impacts of the COVID-19 Outbreak in China (4/21/2020)
Coronavirus Puts Big Pharma’s IP Regime to the Test (4/21/2020)
NHSA Drafts the Guidance Opinions for Dr...  (6/5/2020)
China Issues the Notice for Highlights o...  (6/5/2020)
Recent Executive Moves  (6/5/2020)
CDE Solicits Comments on the Technical G...  (6/5/2020)
CDE Solicits Comments on the Technical G...  (6/5/2020)
USTR Satisfied with China's Implementati...  (6/4/2020)
Beijing Plans to Criminalize Criticisms ...  (6/4/2020) (free)
Everest Medicines Completes $310 Million...  (6/4/2020)
Oncodesign Establishes Strategic Allianc...  (6/3/2020)
BeiGene Announces the Approval of BRUKIN...  (6/3/2020)
Stada Eyes Increased API Sourcing from a...  (6/3/2020)
CDE Seeks Comments on Draft ICH Guidelin...  (6/3/2020)
Sanofi Genzyme's Aldurazyme Approved in ...  (6/3/2020)
Harbour BioMed Announces IND Approval fo...  (6/3/2020)
Innovent Announces the Preliminary Resul...  (6/3/2020)
Pfizer to Absorb Mylan, Creating Global Generic Powerhou...
PhRMA Calls for Trade Deals That Force Countries to Pay ...
IQVIA: Global Pharma to Grow Slower in the Next Five Yea...
Pfizer and GSK Announce JV to Create a Global Consumer H...
Top 25 Global Pharmaceutical Companies by Market Cap 201...
SMEI Bluebook 2020: Chinese Retail Pharmacy Market (Offline and...
SMEI Bluebook 2020: Urban and County Level Public Hospital Drug...
NH Reports 5% Growth for 2019 OTC Gastrointestinal Market in Ch...
Data Snapshot and Outlook of the Chinese Chronic Disease Market...
Asia Pacific Biopharma Contract Manufacturing Market Rise 8.8% ...
Everest Medicines Completes $310 Million Series C Financing
Oncodesign Establishes Strategic Alliance with HitGen to Str...
BeiGene Announces the Approval of BRUKINSA (Zanubrutinib) in...
Stada Eyes Increased API Sourcing from and Presence in China...
Sanofi Genzyme's Aldurazyme Approved in China through Priori...
CDE Solicits Comments on the Technical Guidelines for Cl...
CDE Solicits Comments on the Technical Guidelines for Cl...
CDE Seeks Comments on Draft ICH Guideline Q12
CDE Solicits Feedbacks on Draft Technical Guidance for P...
CDE Solicits Feedbacks on Draft Technical Guidance for P...
Beijing Plans to Criminalize Criticisms of Traditional Chine...
NPC to Prioritize Legislation on Public Health in 2020
China Tops PCT International Patent Filings
Chinese Courts Concludes over 475,000 IPR Cases in 2019
China's Supreme Court Claims Tightened IP Protection
Snapshot of the Chinese API Sector
India to Boost API Output as Alternative Source to China...
India Lifts Export Restrictions on 24 APIs
China Claims Resumption of API Manufacture as Freight an...
China Vows to Further Stabilize Production, Supply of Ac...
Harbour BioMed Announces IND Approval for HBM9161 by NMP...
Innovent Announces the Preliminary Results of the Anti-C...
Inventiva Secures A New Patent for lanifibranor in China...
Henlius and Accord Receive Positive CHMP Opinion for Bio...
Chi-Med Plans to Submit NDA for Surufatinib Following Pr...
NHSA Drafts the Guidance Opinions for Drug Price and Ten...
China Issues the Notice for Highlights of Correction of ...
Healthcare-related Highlights: Premier Li Delivers 2020 ...
Shanghai Tongji Hospital Co-founds Online Medical Platfo...
Snapshot of BMI System Financial Performance in Q1/2020
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
USTR Satisfied with China's Implementatin of Phase 1 US-...
U.S.-China ESRC Hearing: China’s Evolving Healthcare Sy...
AmCham Survey: Supply Chain Challenges for US Companies ...
Upcoming Event: 2nd World Congress on Dermatology and Ae...
Upcoming Event: XI International Exhibition of Equipment...
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON Publishes the China Phar...
  WiCON to Hold Pharma China Ann...
  WiCON Publishes the China Phar...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Chi...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links